As examples, TP53 pathway aberrations status and pPSS (TP53 additive trait) showed a strong OS prognostic value in LIHC tumors (Fig. 4b), Cell Cycle pathway aberrations status and pPSS (Cell Cycle dominant trait) demonstrated OS prognostic value in MESO tumor (Fig. 4c), NOTCH UP pathway aberrations status and pPSS (NOTCH UP recessive trait) demonstrated PFI prognostic value in PRAD (Fig. 4d) and PI3K DEG pathway aberrations status and pPSS (PI3K DEG additive trait) showed significant PFI prognostic value in UCEC tumors (Fig. 4e). The gene discussed is TP53; the disease is prostate adenocarcinoma.